Novartis

News

NICE backs Cosentyx' use in thousands of children with psori...

NICE has recommended broadening NHS use of Novartis' IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis.

News

Novartis' transplant drug hope iscalimab flunks mid-stage tr...

Novartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have been dashed after its iscalimab candidate failed a mid-phase trial.

News

NICE backs NHS use of Novartis' cholesterol drug Leqvio

Novartis' cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.

News

Novartis' bid to extend Kymriah into earlier use hits a road...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

News

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including

News

Europe has its first Lucentis biosimilar, Samsung Bioepis' B...

Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz.

NICE backs Cosentyx' use in thousands of children with psori...

Novartis' transplant drug hope iscalimab flunks mid-stage tr...

NICE backs NHS use of Novartis' cholesterol drug Leqvio

Novartis' bid to extend Kymriah into earlier use hits a road...

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

Europe has its first Lucentis biosimilar, Samsung Bioepis' B...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks